Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Metronidazole modified-release - FORMAC Pharmaceuticals

Next Previous
Search
Drug Profile

Metronidazole modified-release - FORMAC Pharmaceuticals

Alternative Names: FP-110

Latest Information Update: 25 Dec 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FORMAC Pharmaceuticals
  • Class Antibacterials; Antiprotozoals; Nitroimidazoles; Radiosensitisers; Skin disorder therapies; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pouchitis
  • New Molecular Entity No
  • Available For Licensing Yes - Pouchitis

Highest Development Phases

  • No development reported Pouchitis

Most Recent Events

  • 17 Sep 2015 No recent reports on development identified - Phase-II for Pouchitis in Belgium (PO)
  • 10 Mar 2011 Metronidazole modified release - FORMAC Pharmaceuticals is available for licensing as of 10 Mar 2011. http://www.formacpharma.com
  • 09 Mar 2011 Metronidazole modified release - FORMAC Pharmaceuticals receives Orphan Drug status for Pouchitis in Europe

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top